Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

https://ift.tt/os9kIx3

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/ZzGk5B0
via IFTTT https://ift.tt/UkPpiun

SHARE

Milan Tomic

Hi. I’m Designer of Blog Magic. I’m CEO/Founder of ThemeXpose. I’m Creative Art Director, Web Designer, UI/UX Designer, Interaction Designer, Industrial Designer, Web Developer, Business Enthusiast, StartUp Enthusiast, Speaker, Writer and Photographer. Inspired to make things looks better.

• 
• 
• 
• 
•